Antileukaemic

Wulignan A1
Catalog No: CFN99005

Wulignan A1 exhibits activity against leukemia P-388 in vitro; it also may have anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities.
Piceatannol
Catalog No: CFN99024

Piceatannol has antitumor, antioxidant, and anti-inflammatory activities, it also has the potential to control obesity. Piceatannol inhibits effector T cell functions by suppressing TcR signaling.
Ganodermanondiol
Catalog No: CFN99085

Ganodermanondiol exhibits potent cytoprotective effects on t-BHP-induced hepatotoxicity in human liver-derived HepG2 cells, presumably through Nrf2-mediated antioxidant enzymes and AMPK. It also can significantly inhibit the proliferation of leukemic cancer cells, and it could be one of the antileukemie active constituents of Ganoderma lucidum. Ganodermanondiol shows a strong anticomplement activity against the classical pathway (CP) of the complement system with IC(50) values of 41.7 microM. It shows significant anti-human immunodeficiency virus (anti-HIV)-1 protease activity with IC50 values of 20-90 microM.
Dihydroartemisinin
Catalog No: CFN99507

Dihydroartemisinin is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs, recommended as the first-line anti-malarial drug with low toxicity. Dihydroartemisinin has anticancer activity, it inhibited cell proliferation via AKT/GSK3β/cyclinD1/ERK pathway and induced apoptosis is associated with inhibition of Sarco/Endoplasmic reticulum Calcium ATPase activity in colorectal cancer.
Hispidulin
Catalog No: CFN99491

Hispidulin has anti-oxidative, anti-inflammatory, anti-cancer, antiepileptic, neuroprotective, anti-osteoporotic and bone resorption attenuating effects, it targets the VEGF receptor 2-mediated PI3K/Akt/mTOR signaling pathway in endothelial cells, leading to the suppression of pancreatic tumor growth and angiogenesis. Hispidulin can ameliorate high glucose-mediated endothelial dysfunction via inhibiting PKCβII-associated NLRP3 inflammasome activation and NF-κB signaling, it has potential application in the prevention and treatment of diabetic vascular complications. Hispidulin can inhibit platelet aggregation by elevating cAMP levels by a mechanism different from that of theophylline or PGE1.